Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Intense regulated pulse light for meibomian gland dysfunction: early results

Search Title by author or title

Session Details

Session Title: Quality of Vision and Dry Eye

Session Date/Time: Sunday 08/10/2017 | 08:00-09:30

Paper Time: 08:12

Venue: Room 3.4

First Author: : E.Karaca TURKEY

Co Author(s): :    O. Evren Kemer   D. Ozek                 

Abstract Details

Purpose:

To assess the effect of intense regulated pulse light ( E-Eye, E-Swin, France) on the treatment of meibomian gland dysfunction (MGD).

Setting:

Health Sciences University, Ankara Numune Education and Research Hospital, Department of Ophthalmology

Methods:

Thirteen patients underwent IPL treatment (E-Eye, E-Swin, France), with homogeneously sequenced 5 light pulses delivered to one eye at 1, 15 and 45 days following baseline (BL) evaluation. At each visit, subjective clinical parameters (ocular surface disease index (OSDI) questionnaire and standard patient evaluation of eye dryness (SPEED) questionnaire) and objective clinical parameters (Schirmer I test scores, tear break up times (TBUT), Oxford grading, lid margin abnormality score, secretion quality and expressibility degree) were recorded. The subjective and objective parameters at Day 15 and Day 45 were compared with BL values.

Results:

Patients underwent 3 IPL treatment. Schirmer test and tear break-up time improved significantly from BL to Day (D) 45 (8.53±4.31 mm versus 12.6±3.14 mm, 4.53±1.33 sn versus 11,07±2.87 sn, p=0.03 and p<0.001). OSDI and SPEED scores improved from BL to D15, BL to D45 (all with p<0.05). All of the subjects reported reduced symptoms by D45. There were no cases of adverse ocular effects. There was no significant change in Oxford grading, lid margin abnormality score, secretion quality and expressibility degree.

Conclusions:

Intense regulated pulse light seems a safe treatment procedure for MGD, improving tear film quality and reducing symptoms of dry eye.

Financial Disclosure:

NONE

Back to previous